Sandbox Reserved 994
From Proteopedia
(Difference between revisions)
(Added background information.) |
|||
| Line 6: | Line 6: | ||
== Background == | == Background == | ||
| - | Bacteria have cell walls which are largely made of a material called peptidoglycan, composed of | + | Bacteria have cell walls which are largely made of a material called peptidoglycan, composed of NAM and NAG, which the cell uses to protect against lysis from changing osmotic pressure. These two materials make alternating links of NAM and NAG which are held next to each other by NAM cross links. Without this forming, the bacterial cell wall cannot hold its structure against more hypotonic solutions and the cell will lyse and die. Beta-lactams are a group of antibiotics that block the NAM cross linking in the bacterial cell wall by “irreversibly binding to the enzymes that cross-link NAM subunits.<ref>Bauman, Robert W. "Controlling Microbial Growth in the Body: Antimicrobial Drugs." In Microbiology with Diseases by Taxonomy, 287-288. 4th ed. Glenview, IL: Pearson, 2014. </ref>” Beta-lactams are a family of antibiotics that have a four membered ring called a beta-lactam ring. To answer for this, bacterial cells have developed enzymes called beta-lactamases that will hydrolyze the bond between the ring’s acyl group and its nitrogen.<ref>Bauman, Robert W. "Controlling Microbial Growth in the Body: Antimicrobial Drugs." In Microbiology with Diseases by Taxonomy, 299. 4th ed. Glenview, IL: Pearson, 2014. </ref> |
| - | Acinetobacter baumannii is a strain of bacteria resistant to a large amount of | + | Acinetobacter baumannii is a strain of bacteria which is resistant to a large amount of β-lactams and produces three different types of β-lactamases; it was also involved in a nosocomial outbreak in Spain.<ref name = AB> Bou, German, Antonio Oliver, and Jesus Martinez-Beltran. "OXA-24, a Novel Class D β-Lactamase with Carbapenemase Activity in an Acinetobacter Baumannii Clinical Strain." Antimicrobial Agents and Chemotherapy 44, no. 6 (2000): 1556-561. Accessed February 19, 2015. http://aac.asm.org/content/44/6/1556.full</ref> It is dangerous in hospitals because its antibacterial resistance allows it to infect patients who are taking antibiotics. By taking antibiotics, they are clearing out their system and clearing the way for this bacteria to take over.<ref> Dijkshoorn, Lenie, Alexandr Nemec, and Harald Seifert. "An Increasing Threat in Hospitals: Multidrug-resistant Acinetobacter Baumannii." Nature Reviews Microbiology 5, no. 12 (2007): 939-51. Accessed February 19, 2015. http://www.nature.com/nrmicro/journal/v5/n12/full/nrmicro1789.html </ref> This strain of bacteria uses three different β-lactamases to protect itself from antibiotics, one of which is a newly discovered enzyme called OXA-24 β-lactamase. This enzyme is inhibited by chloride ions, tazobactam, sulbactam, and clavulanic acid; and specifically counteracts benzylpenicillin and cephaloridine.<ref name = AB /> |
| - | OXA-24 is a member of the carbapenem-hydrolyzing class D β-lactamases (CHDLs) | + | OXA-24 is a member of the carbapenem-hydrolyzing class D β-lactamases (CHDLs) and is expressed as a resistance mechanism by the bacteria Acinetobacter baumannii. Class D β-lactamases are clinically dangerous because they hydrolyze β-lactam antibiotics such as penicillins, cephalosporins, and carbapenems. Class D β-lactamases are classified as OXA’s, which is in reference to their class designation as oxacillinases; however the terminology is somewhat misleading. While they do have very strong affinity for the antibiotic oxacillin<ref name="Leonard">DOI: 10.1021/ar300327a</ref>; the OXA’s have expanded since their discovery to include penillinase, cephalosporinase, and carbapenemase activity in their spectrum. Due to their original designation as oxacillinases, however, the assignment of the prefix OXA has continued to be standard designation. |
== Bacterial Resistance == | == Bacterial Resistance == | ||
| - | Since the discovery of penicillin by Alexander Flemming in 1928, antibiotics have revolutionized the medical world. Penicillin is known as a β-lactam antibiotic, which is characterized by a four-membered β-lactam ring (a cyclic amide). There are four classes of β-lactam antibiotics: monobactams, which are the simplest class of β-lactam | + | Since the discovery of penicillin by Alexander Flemming in 1928, antibiotics have revolutionized the medical world. Penicillin is known as a β-lactam antibiotic, which is characterized by a four-membered β-lactam ring (a cyclic amide). There are four classes of β-lactam antibiotics: monobactams, which are the simplest class of β-lactam and aren’t fused to any rings; penicillins, which have a thiazole ring fused to the β-lactam; cephalosporins, which contain a thiazine ring; and lastly carbapenems, which are fused with a pyrrole ring and are considered a last line of defense. <ref>doi:10.3390/antibiotics3020128#sthash.iyPihLj1.dpuf</ref> β-lactam antibiotics are the most widely used class of antibiotics because they successfully fight most bacterial infections by inhibiting cell wall synthesis. Their mechanism of action is through inhibition of the transpeptidas enzymes, which are located in the bacterial cell membrane. Transpeptidase is alternatively referred to as a penicillin-binding protein (PBP) and is responsible for catalyzing the cross-linking of the bacterial cell wall <ref>PMCID: PMC162717</ref>. β-lactams mimic the structure of the terminal D-alanine chain of peptidoglycan and irreversibly bind to PBP, disrupting the cross-linking process that is critical to cell wall synthesis. As a result, the bacterial cell wall is compromised and the bacteria lyse and die.<ref>Patrick, G. (2005). Antibacterial Agents. An Introduction to Medicinal Chemistry (3rd Ed), pages 388-414. </ref> |
| - | Due to overperscription and misuse of antibiotics, bacteria have been able to develop resistance mechanisms. One of these resistance mechanisms is through the expression of β-lactamases, which have evolved as a seperate enzyme over millions of years from PBP.<ref>Meroueh, S.O; Minasov, G; Lee, W; Shoichet, B.K; Mobashery, S. Structural aspects for evolution of beta-lactamases from penicillin-binding proteins. J. Am. Chem Soc. (2003), 125, 9612-9618. </ref> β-lactamases act by hydrolyzing the β-lactam ring, which renders the antibiotic inactive before it has a chance to inhibit the transpeptidase enzymes.<ref>Neu, Harold. "The Crisis in Antibiotic Resistance." Science (1992) 257, 5073. ProQuest Medical Library: p. 1064-1072.</ref> β-lactamases are grouped into four different classes (A, B, C and D) | + | Due to overperscription and misuse of antibiotics, bacteria have been able to develop resistance mechanisms. One of these resistance mechanisms is through the expression of β-lactamases, which have evolved as a seperate enzyme over millions of years from PBP.<ref>Meroueh, S.O; Minasov, G; Lee, W; Shoichet, B.K; Mobashery, S. Structural aspects for evolution of beta-lactamases from penicillin-binding proteins. J. Am. Chem Soc. (2003), 125, 9612-9618. </ref> β-lactamases act by hydrolyzing the β-lactam ring, which renders the antibiotic inactive before it has a chance to inhibit the transpeptidase enzymes.<ref>Neu, Harold. "The Crisis in Antibiotic Resistance." Science (1992) 257, 5073. ProQuest Medical Library: p. 1064-1072.</ref> β-lactamases are grouped into four different classes (A, B, C and D); all of which, with the exception of class B, use a serine based mechanism for destruction of β-lactams. Class B β-lactamases use zinc ions for hydrolysis. Class D was distinguished from other serine β-lactamases in the late 1980s, due to having an affinity for oxacillin as its substrate in addition to other antibiotics.<ref>doi: 10.1128/AAC.01009-09</ref> Even more concerning is that the class D β-lactamases, or OXAs, are not inhibited by current clinical β-lactamase inhibitors such as clavulanic acid. OXA-24, which has considerable carbapenemase activity, poses a dangerous clinical threat due to the absence of an effective inhibitor. |
== Structure == | == Structure == | ||
| - | OXA-24 is a monomeric protein | + | OXA-24 is a monomeric protein with an active site composed of a short α-helix and a β-sheet. The active site of OXA-24 is characterized by a hydrophobic pocket, which is representative of Class D β-lactamases as a whole. The hydrophobic bridge contributes to the substrate specificity for carbapenems and is composed of an arrangement of the Tyr-112 and Met-223 side chains.<ref name="Santillana">PMCID: PMC1838445</ref> These residues block the active site and only allow a very specific binding configuration of antibiotics. The active site is overall positively charged and contains a sulfate ion along with other solvent molecules when no substrate is bound. The mechanism of attack is through the use of three catalytic residues: Serine-81, Carboxylated Lysine-84, and Serine-128. The hydroxyl chain of Ser-128 conforms in the direction of the active-serine Ser-81, and contributes to the catalytic mechanism.<ref name="Santillana" /> |
== Hydrolysis Mechanism == | == Hydrolysis Mechanism == | ||
| Line 40: | Line 40: | ||
In step four (D), The enzyme is successfully regenerated and the hydrolyzed β-lactam antibiotic is released back into solution. OXA-24 is now free to hydrolyze another substrate and the antibiotic has been rendered useless.<ref name="Leonard" /> | In step four (D), The enzyme is successfully regenerated and the hydrolyzed β-lactam antibiotic is released back into solution. OXA-24 is now free to hydrolyze another substrate and the antibiotic has been rendered useless.<ref name="Leonard" /> | ||
| - | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | + | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or by loading and editing one of these sample scenes. |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 03:39, 27 February 2015
| This Sandbox is Reserved from 20/01/2015, through 30/04/2016 for use in the course "CHM 463" taught by Mary Karpen at the Grand Valley State University. This reservation includes Sandbox Reserved 987 through Sandbox Reserved 996. |
To get started:
More help: Help:Editing |
OXA-24 β-lactamase
| |||||||||||
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
- ↑ Bauman, Robert W. "Controlling Microbial Growth in the Body: Antimicrobial Drugs." In Microbiology with Diseases by Taxonomy, 287-288. 4th ed. Glenview, IL: Pearson, 2014.
- ↑ Bauman, Robert W. "Controlling Microbial Growth in the Body: Antimicrobial Drugs." In Microbiology with Diseases by Taxonomy, 299. 4th ed. Glenview, IL: Pearson, 2014.
- ↑ 5.0 5.1 Bou, German, Antonio Oliver, and Jesus Martinez-Beltran. "OXA-24, a Novel Class D β-Lactamase with Carbapenemase Activity in an Acinetobacter Baumannii Clinical Strain." Antimicrobial Agents and Chemotherapy 44, no. 6 (2000): 1556-561. Accessed February 19, 2015. http://aac.asm.org/content/44/6/1556.full
- ↑ Dijkshoorn, Lenie, Alexandr Nemec, and Harald Seifert. "An Increasing Threat in Hospitals: Multidrug-resistant Acinetobacter Baumannii." Nature Reviews Microbiology 5, no. 12 (2007): 939-51. Accessed February 19, 2015. http://www.nature.com/nrmicro/journal/v5/n12/full/nrmicro1789.html
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 Leonard DA, Bonomo RA, Powers RA. Class D beta-lactamases: a reappraisal after five decades. Acc Chem Res. 2013 Nov 19;46(11):2407-15. doi: 10.1021/ar300327a. Epub 2013 Jul, 31. PMID:23902256 doi:http://dx.doi.org/10.1021/ar300327a
- ↑ doi: https://dx.doi.org/10.3390/antibiotics3020128#sthash.iyPihLj1.dpuf
- ↑ PMCID: PMC162717
- ↑ Patrick, G. (2005). Antibacterial Agents. An Introduction to Medicinal Chemistry (3rd Ed), pages 388-414.
- ↑ Meroueh, S.O; Minasov, G; Lee, W; Shoichet, B.K; Mobashery, S. Structural aspects for evolution of beta-lactamases from penicillin-binding proteins. J. Am. Chem Soc. (2003), 125, 9612-9618.
- ↑ Neu, Harold. "The Crisis in Antibiotic Resistance." Science (1992) 257, 5073. ProQuest Medical Library: p. 1064-1072.
- ↑ Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010 Mar;54(3):969-76. doi: 10.1128/AAC.01009-09., Epub 2009 Dec 7. PMID:19995920 doi:http://dx.doi.org/10.1128/AAC.01009-09
- ↑ 14.0 14.1 PMCID: PMC1838445
- ↑ Bou G, Oliver A, Martinez-Beltran J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother. 2000 Jun;44(6):1556-61. PMID:10817708

